Aktuelle Nachrichten zu Adaptive Biotechnologies
Portfoliocheck: Fidelity National Information Services ist Andreas Halvorsens Trumpf im War on Cash
Ole Andreas Halvorsen managt in seinem Viking Global Hedgefonds mehr inzwischen als 27 Milliarden Dollar und erzielte in den vergangenen 19 Jahren für seine Anleger eine durchschnittliche Jahresrendite...
IPO-RADAR (HF Enterprise, Inhibikase Therapeutics, In8Bio, The RealReal,...)
Das der Optimismus bei den US-Unternehmen weiter hoch, zeigen die Börsengänge in dieser Woche. Zwei Biotech- und zwei Finanzierungsunternehmen wollen den Sprung an die Börse wagen.- ‹
- 1
- ›
Aktuelle Nachrichten anderer Redaktionen zu Adaptive Biotechnologies
Adaptive Biotech (ADPT) Earnings Call Transcript
Image source: The Motley Fool.DateFeb. 5, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Chad RobinsChief Financial Officer — Kyle PiskelChief Commercial Officer — Susan BobulskyChief Business Development and Partnerships Officer — Sharon BenzenoTakeawaysTotal company revenue -- $277 million for 2025, up 55% year over year, including 51% growth to $71.7 million in the fourth quarter.MRD revenue -- $212 million in 2025, increasing 46% with clinical clonoSEQ testing revenue up...
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +52.63% and -0.44%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies soars after beating Q4 expectations By Investing.com
Adaptive Biotechnologies soars after beating Q4 expectations
Adaptive Biotechnologies stock soars after strong Q4 revenue beat By Investing.com
Adaptive Biotechnologies stock soars after strong Q4 revenue beat
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +6.25% and +38.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Heres What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings call transcript: Adaptive Biotechnologies beats Q2 2025 forecasts By Investing.com
Earnings call transcript: Adaptive Biotechnologies beats Q2 2025 forecasts
Adaptive Biotechnologies soars 8.5% as MRD business achieves profitability By Investing.com
Adaptive Biotechnologies soars 8.5% as MRD business achieves profitability
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Lets find out.
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Adaptive Biotechnologies stock soars on Q1 earnings beat By Investing.com
Adaptive Biotechnologies stock soars on Q1 earnings beat
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 11.54% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.